We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+8.51%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$342M
AUM Growth
+$89.9M
Cap. Flow
+$78.3M
Cap. Flow %
22.9%
Top 10 Hldgs %
35.24%
Holding
113
New
44
Increased
16
Reduced
11
Closed
37

Top Buys

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$9.51M
2
DXCM icon
DexCom
DXCM
+$8.48M
3
AGN
Allergan plc
AGN
+$8.14M
4
CNC icon
Centene
CNC
+$6.89M
5
INCY icon
Incyte
INCY
+$6.33M

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$10M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$8.72M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$6.55M
4
NXTM
NxStage Medical Inc.
NXTM
+$5.56M
5
QGENF
QIAGEN NV
QGENF
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 49.95%
2 Industrials 2.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
51
CALL
DexCom
DXCM
$33.1B
$2.69M 0.79%
+220,000
New +$3.89M
QGEN icon
52
CALL
Qiagen
QGEN
$9.04B
$2.52M 0.74%
+75,444
New +$2.6M
SRPT icon
53
Sarepta Therapeutics
SRPT
$1.81B
$2.27M 0.66%
50,000
+20,000
+67% +$799K
ZGNX
54
CALL
DELISTED
Zogenix, Inc.
ZGNX
$2.19M 0.64%
+62,600
New +$850K
PTCT icon
55
CALL
PTC Therapeutics
PTCT
$6.23B
$2.06M 0.6%
+102,800
New +$2.01M
MOH icon
56
Molina Healthcare
MOH
$10.4B
$1.72M 0.5%
+25,000
New +$1.63M
AERI
57
PUT
DELISTED
Aerie Pharmaceuticals
AERI
$1.71M 0.5%
+35,200
New +$1.92M
SVRA icon
58
Savara
SVRA
$1.17B
$1.62M 0.47%
173,023
-26,977
-13% -$175K
NSTG
59
CALL
DELISTED
NanoString Technologies, Inc.
NSTG
$1.62M 0.47%
+100,000
New +$1.54M
ZGNX
60
DELISTED
Zogenix, Inc.
ZGNX
$1.4M 0.41%
+40,000
New +$543K
RVNC
61
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.38M 0.4%
+50,000
New +$1.21M
DCPH
62
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.33M 0.39%
+70,000
New +$1.28M
AGRX
63
DELISTED
Agile Therapeutics
AGRX
$1.29M 0.38%
145
+58
+67% +$445K
COLL icon
64
Collegium Pharmaceutical
COLL
$882M
$1.23M 0.36%
+117,131
New +$1.29M
QDEL icon
65
PUT
QuidelOrtho
QDEL
$938M
$1.23M 0.36%
+28,000
New +$975K
EXEL icon
66
CALL
Exelixis
EXEL
$13.1B
$1.23M 0.36%
+50,600
New +$1.35M
RGNX icon
67
Regenxbio
RGNX
$688M
$1.12M 0.33%
33,920
+5,100
+18% +$115K
ESRX
68
CALL
DELISTED
Express Scripts Holding Company
ESRX
$950K 0.28%
15,000
– –
INDP icon
69
Indaptus Therapeutics
INDP
$159M
$895K 0.26%
+45
New +$649K
BCRX icon
70
BioCryst Pharmaceuticals
BCRX
$2.51B
$786K 0.23%
150,000
+50,000
+50% +$256K
STDY
71
DELISTED
SteadyMed Ltd
STDY
$721K 0.21%
215,214
– –
STML
72
DELISTED
Stemline Therapeutics, Inc.
STML
$666K 0.19%
60,000
– –
LITS
73
CALL
Lite Strategy Inc
LITS
$29.6M
$527K 0.15%
+9,825
New +$545K
SGYP
74
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$290K 0.08%
100,000
-167,800
-63% -$572K
FOMX
75
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$134K 0.04%
24,100
– –
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q3 2017 Portfolio in Review

As of Q3 2017, Pura Vida Investments held 113 positions worth $342M, up 36% from $252M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments deployed $78.3M of net new capital in Q3 2017, opening 44 new positions and adding to 16 existing holdings. Its largest new stake was Dentsply Sirona: 160,000 shares worth $9.57M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 66% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $8.72M trimmed.

  • Pura Vida Investments's largest Q3 2017 buy was Dentsply Sirona: 160,000 shares worth $9.57M.
  • Pura Vida Investments added most to Athenahealth, Inc. in Q3 2017, an estimated $2.31M increase.
  • Pura Vida Investments's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $8.72M.
  • Pura Vida Investments fully exited Labcorp in Q3 2017, selling an estimated $10M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $342M portfolio in Q3 2017.
  • Pura Vida Investments opened 44 new positions and closed 37 in Q3 2017.
  • Pura Vida Investments's portfolio value rose 36% quarter-over-quarter to $342M.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.